CG
JANX icon

Cutler Group’s Janux Therapeutics JANX Stock Holding History

Cutler Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$15K Buy
+400
New +$8.71K ﹤0.01% 1112

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cutler Group's JANX Position: Q1 2024 in Review

Cutler Group opened a new position in Janux Therapeutics (JANX) in Q1 2024: 400 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #1112 among its holdings.

121 funds tracked by Wall St. Rank hold JANX as of Q1 2024.

  • Cutler Group held 400 shares of Janux Therapeutics worth $15K as of Q1 2024.
  • Janux Therapeutics was a new Cutler Group position in Q1 2024.
  • Janux Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1112 holding.
  • 121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.